< Back to latest news & events

Knowledge Hub

Green Light from AG Bot for Unitary Patent in Europe

November 2014

The Opinion of Advocate General Bot, regarding Spain’s actions (CJEU cases C-146/13 and C-147/13) that the Regulations surrounding the creating of the European Unitary Patent should be annulled, has been given today. It is the Opinion of AG Bot that the CJEU should dismiss Spain’s actions.

Spain pleaded that the proposed language scheme would be discriminatory to persons whose mother tongue was not German, French or English. Furthermore, that aspects of EU law had been breached in the arranging of the Regulation on the Unitary Patent and Unified Patent Court.

Today’s press release states that unitary protection “brings real benefit” over the current European Patent Convention, where the effects of European patents are determined by national laws. Furthermore, even though the language arrangements that have been selected under the regime may curtail the use of some European languages, they “pursue a legitimate objective of reducing translation costs”. To limit the number of languages for the European Unitary Patent will reduce costs, and furthermore, acknowledges the linguistic realities of the patent sector (German, French and English are the most popular spoken languages from which patent application in the EU originate, as well as the languages of most published scientific papers).

In both cases brought by Spain, AG Bot proposed that CJEU should dismiss Spain’s actions.

The opinion of the Advocate General is not binding on the CJEU, and judgements will be given at a later stage. However, it is unusual for the Court not to follow the Opinion of the AG. The Opinion signifies a green light for unitary patent protection in Europe.

Latest updates

The FoodTech Series #1 | Medicament, functional food, nutritive product in the same claim 1: when your own examples no longer support the “improvement”

            The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they ruled on an opposition …

Read article

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article